Search results
Showing 61 to 75 of 123 results for nivolumab
Awaiting development [GID-TA11336] Expected publication date: TBC
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued [GID-TA10221]
Cabozantinib for untreated advanced renal cell carcinoma (TA542)
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.
Discontinued [GID-TA10126]
Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]
Discontinued [GID-TA10443]
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued [GID-TA10321]
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
Discontinued [GID-TA10590]
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued [GID-TA10158]
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
In development [GID-TA10841] Expected publication date: TBC
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued [GID-TA10164]